The Effect Of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) As An Adjuvant In Patients With Resectable Pancreatic Cancer
Antonios-Apostolos K Tentes, Konstantinos M. Stamou, Nikolaos Pallas, Christina Karamveri, Dimitrios S. Kyziridis, Christos Hristakis
Published 2016 · Medicine
Download PDFAnalyze on Scholarcy
Abstract Background – aims: The long-term survival of pancreatic cancer is poor even after potentially curative resection. The incidence of local-regional failures is high. There is evidence that hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) is effective in controlling the local-regional failures. The purpose of the study is to identify the effect of HIPEC after surgical removal of pancreatic carcinoma. Patients – Methods: Prospective study including 33 patients with resectable pancreatic carcinomas. All patients underwent surgical resection (R0) and ΗIPEC as an adjuvant. Morbidity and hospital mortality were recorded. The patients were followed-up for 5 years. Survival was calculated. Recurrences and the sites of failure were recorded. Results: The mean age of the patients was 67.8 ± 11.1 years (38–86). The hospital mortality was 6.1% (2 patients) and the morbidity 24.2% (8 patients). The overall 5-year survival was 24%. The mean and median survival was 33 and 13 months, respectively. The median follow-up time was 11 months. The recurrence rate was 60.6% (20 patients). Three patients were recorded with local-regional failures (9.1%) and the others with liver metastases. Conclusions: It appears that HIPEC as an adjuvant following potentially curative resection (R0) of pancreatic carcinoma may effectively control the local-regional disease. Prospective randomised studies are required.
This paper references
One Thousand Consecutive Pancreaticoduodenectomies
John L. Cameron (2006)
Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
Karsten Ridwelski (2002)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
John P Neoptolemos (2004)
Cancer statistics, 2002.
Ahmedin Jemal (2002)
Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study
Yinuo Tu (2016)
Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study.
Simon Roderick Bramhall (1995)
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Thierry Conroy (2011)
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Grace Hwei Ching Tan (2016)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer
Karol Polom (2016)
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology.
Paul H Sugarbaker (1996)
Prognostic factors after surgical resection for pancreatic carcinoma.
Paolo Magistrelli (2000)
Radical resection of pancreatic cancer.
Alexander Koliopanos (2008)
From the FROGHI (French Oncologic and Gynaecologic HIPEC Group)
N Bakrin (2013)
Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas.
Giacomo Benassai (2000)
Theoretical and experimental bases of intraperitoneal chemotherapy.
Robert L. Dedrick (1985)
A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei
Tristan D. Yan (2006)
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Jean H G Klinkenbijl (1999)
Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.
Carlo Riccardo Rossi (2004)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle (2007)
Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
Charles C. Hsu (2009)
Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving?
Samy S. Nitecki (1995)
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
Olivier Glehen (2004)
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma
TD Yan (2007)
Relationship between hospital volume and late survival after pancreaticoduodenectomy.
John D. Birkmeyer (1999)
Oluwole Gbolagunte Ajao (1980)
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Sarcomatosis
Reese W Randle (2013)
Intraperitoneal gemcitabine chemotherapy as an adjuvant treatment for patients with resected pancreatic cancer: Phase II and pharmacologic studies
Paul H Sugarbaker (2012)
Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study
Lilian Schwarz (2016)
Prognostic Factors Following Curative Resection for Pancreatic Adenocarcinoma: A Population-Based, Linked Database Analysis of 396 Patients
Jonathan E Lim (2003)
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Martin H. Kalser (1985)
AL Warshaw (1992)
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
Naoual Bakrin (2013)
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
Tristan D. Yan (2007)
Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.
James L. Speyer (1981)
Prognostic indicators for survival after resection of pancreatic adenocarcinoma.
R J Geer (1993)
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Daniel D. Von Hoff (2011)
Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study.
Bernhard W. Renz (2016)
Update on the management of pancreatic cancer: surgery is not enough.
Daniel Ansari (2015)
Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer
Antonios-Apostolos K Tentes (2012)
Retrospective analyses of trends in pancreatic surgery: indications, operative techniques, and postoperative outcome of 1,120 pancreatic resections
Uwe A Wittel (2015)
Pharmacokinetics of Intraperitoneal Gemcitabine in a Rat Model
Sophie R Pestieau (1998)
Pancreatic cancer--low survival rates.
Hans Günther Beger (2008)
Pancreatic cancer: basic and clinical aspects.
Günter Schneider (2005)
Theoretical and experimental bases of intraperitoneal chemotherapy.
Dedrick Rl (1985)
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial
Timothy J. Eberlein (2008)
This paper is referenced by
Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review
William F. Morano (2018)
Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer.
Antonios-Apostolos K Tentes (2018)
Clinical Trials in CRS and HIPEC: Ongoing Trials and Future Directives
William F. Morano (2018)
The Role for Palliative Surgical Interventions in Pancreatic Cancer
Alexandra G Lopez-Aguiar (2018)
Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis
Feng Cao (2017)
Hyperthermic chemotherapy intra-abdominal laparoscopic approach: development of a laparoscopic model using CO2 recirculation system and clinical translation in peritoneal carcinomatosis
Susana Sánchez-García (2017)
Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC
Hb Jin (2019)
Locoregional peritoneal hyperthermia to enhance the effectiveness of chemotherapy in patients with peritoneal carcinomatosis: a simulation study comparing different locoregional heating systems.
H. Petra Kok (2020)
Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer?
Charles Honoré (2017)
Update on clinical trials in colorectal cancer peritoneal metastasis
Amandine Pinto (2017)
Strategies to improve local control of resected pancreas adenocarcinoma.
Paul H Sugarbaker (2017)
Tumor manipulation during pancreatic resection for pancreatic cancer induces dissemination of tumor cells into the peritoneal cavity: a systematic review.
M Willemijn Steen (2018)